Prevalence of HIV Transmitted Drug Resistance in Nanjing from 2018 to 2021

References

• HIV/AIDS UNPo. Global HIV & AIDS statistics — fact sheet. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed January 4, 2023.
   Google Scholar
• AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition). Zhonghua Nei Ke Za Zhi. 2021;60(12):1106–1128. Chinese. doi:10.3760/cma.j.cn112138-20211006-00676
   PubMedGoogle Scholar
• Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China’s free ART program. Cell Res. 2005;15(11–12):877–882. doi:10.1038/sj.cr.7290362
   PubMed Web of Science ®Google Scholar
• Zhang F, Haberer JE, Wang Y, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS. 2007;21(Suppl 8):S143–S148. doi:10.1097/01.aids.0000304710.10036.2b
   PubMed Web of Science ®Google Scholar
• Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis. 2011;11(7):516–524. doi:10.1016/S1473-3099(11)70097-4
   PubMed Web of Science ®Google Scholar
• Zhang F, Liang B, Liang X, et al. Using molecular transmission networks to reveal the epidemic of pretreatment HIV-1 drug resistance in Guangxi, China. Front Genet. 2021;12:688292. doi:10.3389/fgene.2021.688292
   PubMed Web of Science ®Google Scholar
• Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5(10):e588–e596. doi:10.1016/S2352-3018(18)30173-5
   PubMed Web of Science ®Google Scholar
• Zhao S, Feng Y, Hu J, et al. Prevalence of transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China. Sci Rep. 2018;8(1):12273. doi:10.1038/s41598-018-29202-2
   PubMedGoogle Scholar
• Wang Z, Zhang M, Zhang R, et al. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China. BMC Infect Dis. 2019;19(1):313. doi:10.1186/s12879-019-3927-1
   PubMedGoogle Scholar
• Xu Y, Peng X, Peng X, et al. Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014–2017. Arch Virol. 2018;163(8):2233–2237. doi:10.1007/s00705-018-3839-1
   PubMed Web of Science ®Google Scholar
• Phillips AN, Stover J, Cambiano V, et al. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa. J Infect Dis. 2017;215(9):1362–1365. doi:10.1093/infdis/jix089
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Hamers RL, Noguera-Julian M, et al. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018;5(11):e638–e646. doi:10.1016/S2352-3018(18)30177-2
   PubMed Web of Science ®Google Scholar
• Yeganeh N, Kerin T, Ank B, et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study. Clin Infect Dis. 2018;66(11):1770–1777. doi:10.1093/cid/cix1104
   PubMed Web of Science ®Google Scholar
• Riou J, Dupont C, Bertagnolio S, et al. Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine Southern African countries: a modelling study. BMC Infect Dis. 2021;21(1):1042. doi:10.1186/s12879-021-06757-6
   PubMed Web of Science ®Google Scholar
• Rhee SY, Kassaye SG, Barrow G, Sundaramurthi JC, Jordan MR, Shafer RW. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. J Int AIDS Soc. 2020;23(9):e25611. doi:10.1002/jia2.25611
   PubMed Web of Science ®Google Scholar
• Kantzanou M, Karalexi MA, Papachristou H, Vasilakis A, Rokka C, Katsoulidou A. Transmitted drug resistance among HIV-1 drug-naïve patients in Greece. Int J Infect Dis. 2021;105:42–48. doi:10.1016/j.ijid.2021.02.043
   PubMed Web of Science ®Google Scholar
• É Á, Müller V, Mezei M, et al. Transmitted drug resistance in newly diagnosed and treatment-naïve HIV type 1-infected patients in Hungary. J Glob Antimicrob Resist. 2020;20:124–130. doi:10.1016/j.jgar.2019.07.014
   PubMed Web of Science ®Google Scholar
• Chan W, Ly W. Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County. Heliyon. 2019;5(9):e02411. doi:10.1016/j.heliyon.2019.e02411
   PubMed Web of Science ®Google Scholar
• Ross LL, Shortino D, Shaefer MS. Changes from 2000 to 2009 in the prevalence of HIV-1 containing drug resistance-associated mutations from antiretroviral therapy-naive, HIV-1-infected patients in the United States. AIDS Res Hum Retroviruses. 2018;34(8):672–679. doi:10.1089/aid.2017.0295
   PubMed Web of Science ®Google Scholar
• Ye J, Hao M, Xing H, et al. Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001–2016. PLoS One. 2020;15(3):e0230779. doi:10.1371/journal.pone.0230779
   PubMed Web of Science ®Google Scholar
• Organization WH. HIV drug resistance report 2021; 2021. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/9789240038608-eng.pdf. Accessed January 4, 2023.
   Google Scholar
• Guo H, Xu X, Hu H, et al. Low prevalence of the transmitted HIV-1 drug resistance among newly diagnosed HIV-1 individuals in Jiangsu Province, China during 2009–2011. BMC Public Health. 2015;15:120. doi:10.1186/s12889-015-1489-8
   PubMed Web of Science ®Google Scholar
• Li R, Song C, Chen D, et al. Prevalence of transmitted drug resistance among ART-naïve HIV-infected individuals, Beijing, 2015–2018. J Glob Antimicrob Resist. 2022;28:241–248. doi:10.1016/j.jgar.2022.01.017
   PubMed Web of Science ®Google Scholar
• Lan Y, Li L, He X, et al. Transmitted drug resistance and transmission clusters among HIV-1 treatment-naïve patients in Guangdong, China: a cross-sectional study. Virol J. 2021;18(1):181. doi:10.1186/s12985-021-01653-6
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao B, An M, et al. Transmitted drug resistance to tenofovir/emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018. BMC Infect Dis. 2021;21(1):668. doi:10.1186/s12879-021-06312-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global strategy for the surveillance and monitoring of HIV drug resistance; 2012. Available from: https://www.who.int/hiv/pub/drugresistance/drug_resistance_strategy/en/. Accessed January 4, 2023.
   Google Scholar
• Zuo L, Liu K, Liu H, et al. Corrigendum to “Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001–2017)” [EClinicalMedicine 18 (2020) 100238]. EClinicalMedicine. 2021;33:100696. doi:10.1016/j.eclinm.2020.100696
   PubMedGoogle Scholar
• Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 integrase inhibitors: a comparative review of efficacy and safety. Drugs. 2020;80(16):1649–1676. doi:10.1007/s40265-020-01379-9
   PubMed Web of Science ®Google Scholar
• Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–355. doi:10.1016/S1473-3099(17)30702-8
   PubMed Web of Science ®Google Scholar
• World Health Orgnization. Guidelines on the public health response to pretreatment HIV drug resistance; 2021. Available from: https://www.who.int/publications/i/item/9789241550055. Accessed January 4, 2023.
   Google Scholar
• Pang X, Tang K, He Q, et al. HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China. BMC Infect Dis. 2021;21(1):160. doi:10.1186/s12879-021-05854-w
   PubMed Web of Science ®Google Scholar
• Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307. doi:10.1016/j.meegid.2016.08.031
   PubMed Web of Science ®Google Scholar
• Liu M, He XQ, Deng RN, et al. Pretreatment drug resistance in people living with HIV: a large retrospective cohort study in Chongqing, China. HIV Med. 2022;23 Suppl 1(Suppl1):95–105. doi:10.1111/hiv.13253
   PubMedGoogle Scholar
• Obeng BM, Bonney EY, Asamoah-Akuoko L, et al. Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana. Virol J. 2020;17(1):114. doi:10.1186/s12985-020-01386-y
   PubMed Web of Science ®Google Scholar
• Song YX, Xin RL, Li ZC, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339–344. doi:10.1017/S0950268817003016
   PubMed Web of Science ®Google Scholar
• Ye J, Hao M, Xing H, et al. Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: a multicenter observational study. AIDS. 2020;34(4):609–619. doi:10.1097/QAD.0000000000002468
   PubMed Web of Science ®Google Scholar
• Ding Y, Chen M, Wang J, et al. Increase in HIV-1-transmitted drug resistance among ART-naïve youths at the China-Myanmar border during 2009 ~ 2017. BMC Infect Dis. 2021;21(1):93. doi:10.1186/s12879-021-05794-5
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Brumme CJ, Heckerman D, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 2007;3(7):e94. doi:10.1371/journal.ppat.0030094
   PubMed Web of Science ®Google Scholar
• Liu DJ, Feng MX, Liu M. 中国未接受抗病毒治疗的人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)人群HIV原发耐药的Meta分析 [Primary drug resistance of human immunodeficiency virus (HIV)among the treatment-naive individuals with HIV in China: a meta-analysis]. Beijing Da Xue Xue Bao Yi Xue Ban. 2015;47(3):474–482. Chinese.
   PubMedGoogle Scholar
• Liu L, Dai L, Yao J, et al. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China. AIDS. 2019;33(12):1945–1947. doi:10.1097/QAD.0000000000002282
   PubMed Web of Science ®Google Scholar